论文部分内容阅读
目的评价经皮冠状动脉介入治疗(PCI)后,氯吡格雷抵抗患者服用双倍剂量氯吡格雷的有效性及安全性。方法依据血栓弹力图(TEG)的测定结果,将入选的134例氯吡格雷抵抗患者分为常规剂量组67例与双倍剂量组67例,随访观察两组患者PCI术后6个月时临床缺血及出血事件的发生率。结果双倍剂量组与常规剂量组患者相比较,主要不良心血管事件的发生率明显降低,而出血事件发生率在两组患者间比较,差异无统计学意义。结论增加氯吡格雷的维持剂量,可以减少冠心病患者PCI术后缺血事件的发生,且不增加患者的出血风险。
Objective To evaluate the efficacy and safety of double-dose clopidogrel in patients receiving clopidogrel after percutaneous coronary intervention (PCI). Methods Based on the results of thromboelastography (TEG), 134 patients with clopidogrel resistance were divided into conventional dose group (67 cases) and double dose group (67 cases). The follow-up of two groups was observed at 6 months after PCI The incidence of ischemic and bleeding events. Results Compared with the conventional dose group, the incidence of major adverse cardiovascular events was significantly lower in double-dose group and no significant difference was found in the incidence of bleeding between the two groups. Conclusions Increasing the maintenance dose of clopidogrel can reduce the occurrence of ischemic events after PCI in patients with coronary heart disease without increasing the risk of bleeding in patients.